| Pharmaceutical Information |
| Drug Name |
Urokinase |
| Drug ID |
BADD_D02320 |
| Description |
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943]
Urokinase was granted FDA approval on 16 January 1978.[L12138] |
| Indications and Usage |
In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.[L12141] |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
B01AD04 |
| DrugBank ID |
DB00013
|
| KEGG ID |
D03341
|
| MeSH ID |
D014568
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
83G67E21XI
|
| Synonyms |
Urokinase-Type Plasminogen Activator | Urokinase Type Plasminogen Activator | Plasminogen Activator, Urokinase-Type | U-Plasminogen Activator | U Plasminogen Activator | U-PA | Urinary Plasminogen Activator | Urokinase | Renokinase | Abbokinase | Kidney Plasminogen Activator | Single-Chain Urokinase-Type Plasminogen Activator | Single Chain Urokinase Type Plasminogen Activator |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
9039-53-6 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Embolism | 24.01.01.009 | - | - | |
|
|
|
